Elsevier

Stem Cell Research

Volume 12, Issue 2, March 2014, Pages 584-598
Stem Cell Research

Combination of immortalization and inducible death strategies to generate a human mesenchymal stromal cell line with controlled survival

https://doi.org/10.1016/j.scr.2013.12.006Get rights and content
Under a Creative Commons license
open access

Highlights

  • The compatibility between immortalization and inducible-death strategies

  • The generation of the first death-inducible cell line

  • The maintenance of the differentiation and immunomodulatory capacities

  • The non-tumorigenicity of the established cell line

  • A new tool for cell & gene therapy and regenerative medicine discovery

Abstract

The hTERT-immortalization of human bone marrow-derived Mesenchymal Stromal Cells (hMSCs) was proposed to address availability/standardization issues for experimental or clinical studies, but raised concerns due to possible uncontrolled growth or malignant cell transformation.

Here we report a method to generate a hMSCs line with controlled survival, through the implementation of a pre-established suicide system (inducible caspase 9, iCasp9) in hTERT-transduced hMSCs.

Primary hMSCs were successfully immortalized (> 280 PD) and further transduced with the iCasp9 device. A clone was selected and shown to maintain typical properties of primary hMSCs, including phenotype, differentiation and immunomodulation capacities. The successive transductions did not induce tumorigenic transformation, as assessed by analysis of cell cycle regulators and in vivo luciferase-based cell tracking. Cells could be efficiently induced toward apoptosis (> 95%) both in vitro and in vivo.

By combining the opposite concepts of ‘induced-life’ and ‘inducible-death’, we generated a hMSCs line with defined properties and allowing for temporally controlled survival. The cell line represents a relevant tool for medical discovery in regenerative medicine and a potential means to address availability, standardization and safety requirements in cell & gene therapy. The concept of a hTERT-iCasp9 combination, here explored in the context of hMSCs, could be extended to other types of progenitor/stem cells.

Cited by (0)

Author contributions: Paul Bourgine: conception and design, collection and assembly of data, data analysis and interpretation, and manuscript writing; Clementine Le Magnen: collection and assembly of data; Sebastien Pigeot: collection and assembly of data; Jeroen Geurts: provision of study material, data analysis and interpretation; Arnaud Scherberich: conception and design, data analysis and interpretation; Ivan Martin: conception and design, financial support, manuscript writing, and final approval of manuscript.